Evidence map›Paper›PMID 40149929›Full record

ArticleBiomolecules2025

Genetic Analysis and Predictive Modeling of COVID-19 Severity in a Hospital-Based Patient Cohort.

Iraide Alloza-Moral, Ane Aldekoa-Etxabe, Raquel Tulloch-Navarro, Ainhoa Fiat-Arriola, Carmen Mar, Eloisa Urrechaga, Cristina Ponga, Isabel Artiga-Folch, Naiara Garcia-Bediaga, Patricia Aspichueta and 8 more

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Iraide Alloza-MoralInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Ane Aldekoa-EtxabeInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Raquel Tulloch-NavarroInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Ainhoa Fiat-ArriolaInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Carmen MarPneumology Department, Galdakao-Usansolo University Hospital, Biobizkaia Health Research Institute, 48960 Galdakao, Spain.
Eloisa UrrechagaPneumology Department, Galdakao-Usansolo University Hospital, Biobizkaia Health Research Institute, 48960 Galdakao, Spain.ORCID 0000-0002-9610-7392
Cristina PongaPneumology Department, Galdakao-Usansolo University Hospital, Biobizkaia Health Research Institute, 48960 Galdakao, Spain.ORCID 0000-0001-8940-9053
Isabel Artiga-FolchInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Naiara Garcia-BediagaBioinformatic Unit, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Patricia AspichuetaPhysiology Department, Faculty of Medicine and Nursery, Basque Country University (UPV/EHU), 48940 Leioa, Spain.
Cesar MartinInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-4087-8729
Aitor Zarandona-GaraiBioinformatic Unit, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0009-0001-9815-2779
Silvia Pérez-FernándezBioinformatic Unit, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Eunate Arana-ArriClinical Epidemiology Unit, Biobizkaia Health Research Institute, Cruces University Hospital, Plaza de Cruces s/n, 48903 Barakaldo, Spain.
Juan-Carlos TriviñoBioinformatics Department, Sistemas Genómicos, 46980 Peterna, Spain.ORCID 0000-0001-6752-8000
Ane UrangaPneumology Department, Galdakao-Usansolo University Hospital, Biobizkaia Health Research Institute, 48960 Galdakao, Spain.
Pedro-Pablo EspañaPneumology Department, Galdakao-Usansolo University Hospital, Biobizkaia Health Research Institute, 48960 Galdakao, Spain.
Koen Vandenbroeck-van-CaeckenberghInflammation & Biomarkers Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-6967-6485

Funding

basque government 2020333038
6 · The paper itself

Abstract

The COVID-19 pandemic has had a devastating impact, with more than 7 million deaths worldwide. Advanced age and comorbidities partially explain severe cases of the disease, but genetic factors also play a significant role. Genome-wide association studies (GWASs) have been instrumental in identifying loci associated with SARS-CoV-2 infection. Here, we report the results from a >820 K variant GWAS in a COVID-19 patient cohort from the hospitals associated with IIS Biobizkaia. We compared intensive care unit (ICU)-hospitalized patients with non-ICU-hospitalized patients. The GWAS was complemented with an integrated phenotype and genetic modeling analysis using HLA genotypes, a previously identified COVID-19 polygenic risk score (PRS) and clinical data. We identified four variants associated with COVID-19 severity with genome-wide significance (rs58027632 in KIF19; rs736962 in HTRA1; rs77927946 in DMBT1; and rs115020813 in LINC01283). In addition, we designed a multivariate predictive model including HLA, PRS and clinical data which displayed an area under the curve (AUC) value of 0.79. Our results combining human genetic information with clinical data may help to improve risk assessment for the development of a severe outcome of COVID-19.

Indexed as

COVID-19AgedCohort StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansIntensive Care UnitsMaleMiddle AgedPolymorphism, Single NucleotideSARS-CoV-2Severity of Illness IndexCOVID-19GWASHLAKIF19SARS-CoV-2severity

Identifiers

PMID40149929
PMCPMC11940120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.